Stated plainly: 20 mg · 2.5 mL · bacteriostatic water.
The units are where I keep going wrong, so please be explicit about them.
I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.
How many significant figures are actually justified here?
The answer depends on what you want your measurement resolution to be, and that is a real trade-off rather than a preference. More diluent gives you more syringe marks per dose and therefore less rounding error; it also gives you a larger volume to keep cold and a longer period over which the solution has to remain within specification.
If the material arrived warm and it was lyophilised, test it and proceed on the result.
Tilting the vial to pool solution in the corner before the final draw, and giving it a minute to drain down the walls, genuinely recovers ten to twenty microlitres.
Published data on syringe dead space in the context of injection-equipment programmes quantifies low-dead-space designs as retaining under 2 µL against 35 µL or more.
One limitation: technique reduces risk, it does not remove it.
Do the arithmetic twice, ideally with someone else doing it independently.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsRead the cake before you touch the vial. An intact, opaque, evenly distributed puck that sits proud of the vial base is what a good lyophilisation cycle produces. Anything else — collapse, melt-back at the stopper, a glassy film, a cake that has slumped to one side — is evidence about the cycle, the shipping, or both.
Photograph the vial against a matte black card with a single point light source off to one side, not with a flash from the front.
The part that matters: on re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle.
The caveat is that this is not a recommendation to administer anything. Research-use-only material is not approved for human use.
None of this is exotic. It is just the difference between doing it deliberately and doing it approximately.
Before anything else: a kitchen counter with an alcohol wipe is not an aseptic environment, and it is worth being honest about that rather than pretending the procedure is something it is not. What you are doing is reducing bioburden, not achieving sterility.
Room temperature before drawing is worth the ten minutes. Cold solution is more viscous, draws slower, and is more likely to pull a bubble past the plunger seal.
Put another way, the practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing.
Coring of elastomeric closures is a well-characterised failure mode in the parenteral packaging literature.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale.
edited 18 Oct 2024 by dead_volume — removed a claim I could not source
Put another way, the distinction that resolves most of these questions is that bacteriostatic water suppresses microbial growth and does not sterilise anything. It buys you a multiple-withdrawal presentation; it does not make an unsterile preparation sterile, and it does not substitute for technique.
The order of operations matters: temperature first, then diluent measurement, then injection, then gentle dissolution, then labeling.
Worth saying: if your arithmetic and someone else's disagree by a factor of ten, one of you has made a unit error.
Do the arithmetic twice, ideally with someone else doing it independently.
The part that matters: reconstitution is the step where most hands-on errors enter the system, which is why spending time on technique here pays off more than anywhere else.
A 0.22 µm syringe filter will remove particulates and organisms, and it will also adsorb a fraction of your peptide.
The 28-day beyond-use convention for a multiple-withdrawal preserved preparation derives from USP compounding chapters, which set it on microbiological risk rather than chemical stability.
None of this is exotic. It is just the difference between doing it deliberately and doing it approximately.
edited 19 Aug 2024 by lane_transit — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.